HomeCompareGENE vs CL

GENE vs CL: Dividend Comparison 2026

GENE yields 261.44% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GENE wins by $612.76M in total portfolio value
10 years
GENE
GENE
● Live price
261.44%
Share price
$0.77
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$612.80M
Annual income
$349,686,678.74
Full GENE calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — GENE vs CL

📍 GENE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGENECL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GENE + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GENE pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GENE
Annual income on $10K today (after 15% tax)
$22,222.22/yr
After 10yr DRIP, annual income (after tax)
$297,233,676.93/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, GENE beats the other by $297,229,085.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GENE + CL for your $10,000?

GENE: 50%CL: 50%
100% CL50/50100% GENE
Portfolio after 10yr
$306.42M
Annual income
$174,846,040.35/yr
Blended yield
57.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

GENE
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
-24.5
Piotroski
2/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GENE buys
0
CL buys
0
No recent congressional trades found for GENE or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGENECL
Forward yield261.44%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$612.80M$40.8K
Annual income after 10y$349,686,678.74$5,401.96
Total dividends collected$585.16M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusSellHold

Year-by-year: GENE vs CL ($10,000, DRIP)

YearGENE PortfolioGENE Income/yrCL PortfolioCL Income/yrGap
1← crossover$36,844$26,143.79$11,012$312.01+$25.8KGENE
2$129,445$90,022.09$12,196$412.95+$117.2KGENE
3$434,094$295,587.53$13,599$549.66+$420.5KGENE
4$1,390,885$926,404.44$15,288$736.64+$1.38MGENE
5$4,262,362$2,774,115.59$17,353$995.28+$4.25MGENE
6$12,505,839$7,945,111.88$19,926$1,357.80+$12.49MGENE
7$35,167,310$21,786,062.26$23,194$1,873.82+$35.14MGENE
8$94,885,057$57,256,035.19$27,439$2,621.52+$94.86MGENE
9$245,903,396$144,376,384.91$33,088$3,727.38+$245.87MGENE
10$612,803,313$349,686,678.74$40,806$5,401.96+$612.76MGENE

GENE vs CL: Complete Analysis 2026

GENEStock

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Full GENE Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this GENE vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GENE vs SCHDGENE vs JEPIGENE vs OGENE vs KOGENE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.